Please use this identifier to cite or link to this item:
Title: Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
Author: Coghlan, John Gerry
Galiè, Nazzareno
Barberà i Mir, Joan Albert
Frost, Adaani E.
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M
Kuwana, Masataka
McLaughlin, Vallerie V.
Peacock, Andrew J.
Simonneau, Gérald
Vachiéry, Jean-Luc
Blair, Christiana
Gillies, Hunter
Miller, Karen L.
Harris, Julia H. N.
Langley, Jonathan
Rubin, Lewis J.
AMBITION Investigators
Keywords: Hipertensió pulmonar
Malalties autoimmunitàries
Pulmonary hypertension
Autoimmune diseases
Issue Date: 30-Dec-2016
Publisher: BMJ Publishing Group
Abstract: BACKGROUND: Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared with idiopathic PAH in most trials. Thus, there is uncertainty regarding the benefit of PAH-targeted therapy in some forms of CTD-PAH. OBJECTIVE: To explore the safety and efficacy of initial combination therapy with ambrisentan and tadalafil versus ambrisentan or tadalafil monotherapy in patients with CTD-PAH and SSc-PAH enrolled in the AMBITION trial. METHODS: This was a post hoc analysis of patients with CTD-PAH and SSc-PAH from AMBITION, an event-driven, double-blind trial in patients with WHO functional class II/III PAH. Treatment-naive patients were randomised 2:1:1 to once-daily initial combination therapy with ambrisentan plus tadalafil or monotherapy with ambrisentan or tadalafil, respectively. The primary endpoint was time to the first clinical failure event (first occurrence of death, hospitalisation for worsening PAH, disease progression or unsatisfactory long-term clinical response). RESULTS: In the primary analysis set (N=500), 187 patients had CTD-PAH, of whom 118 had SSc-PAH. Initial combination therapy reduced the risk of clinical failure versus pooled monotherapy in each subgroup: CTD-PAH (HR 0.43 (95% CI 0.24 to 0.77)) and SSc-PAH (0.44 (0.22 to 0.89)). The most common AE was peripheral oedema, which was reported more frequently with initial combination therapy than monotherapy in the two PAH subgroups. The relative frequency of adverse events between those on combination therapy versus monotherapy was similar across subgroups. CONCLUSIONS: This post hoc subgroup analysis provides evidence that CTD-PAH and SSc-PAH patients benefit from initial ambrisentan and tadalafil combination therapy.
Note: Reproducció del document publicat a:
It is part of: Annals of the Rheumatic Diseases, 2016, vol. 76, num. 7, p. 1219-1227
Related resource:
ISSN: 0003-4967
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
678531.pdf866.87 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.